Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Efficacy of novel agents in r/r T pro-lymphocytic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 478

Prof Philipp Staber - Medical University of Vienna, Vienna, Austria

Prof Staber speaks with ecancer at EHA 23 about the management TPLL, a rare blood disease, with new agents.

He describes the challenges in trial design for rare diseases, and the drug screening panel used in this assessment to determine the likely activity of ibrutinib.

For more on trial design for rare diseases, watch Dr Gianni Bisogno discuss a trial for rhabdomyosarcoma at ASCO 2018.

Related videos

follow us

ONJ e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence